Sanofi reports sales growth amid Dupixent's China launch, but reveals PDUFA delay in Pompe disease program
Sanofi released its first quarter earnings report Wednesday, and while the company saw positive news regarding growth and sales — particularly in China — they also revealed for the first time a delay in one of their lead Phase III programs.
The French pharma’s Pompe disease program avalglucosidase alfa saw its PDUFA date pushed back by three months, from May 18 to Aug. 18, Sanofi noted in its investor presentation. No reason was given for the move, and Endpoints News has reached out for comment.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.